Glaukos (id:9386 GKOS)
144.75 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/22/2024 12:58:50 PM)
Exchange open, closes in 3 hours 1 minutes
About Glaukos
Market Capitalization 7.64B
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
| Headquarters (address) |
One Glaukos Way Aliso Viejo 92656 CA United States |
| Phone | 949 367 9600 |
| Website | https://www.glaukos.com |
| Employees | 907 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Ticker | GKOS |
| Exchange | New York Stock Exchange |
| Currency | USD |
| 52 week range | 59.22 - 145.84 |
| Market Capitalization | 7.64B |
| P/E trailing | -51.61 |
| P/E forward | -126.02 |
| Price/Sale | 21.21 |
| Price/Book | 11.42 |
| Beta | 1.03 |
| EPS | -2.94 |
| EPS United States (ID:6, base:3395) | 24.30 |